Loading...
Epigenomics AG
EPGNF•PNK
Healthcare
Medical - Diagnostics & Research
$1.12
$0.00(0.00%)

Over the last four quarters, Epigenomics AG achieved steady financial progress, growing revenue from $134000.00 in Q1 2023 to $68114.00 in Q4 2023. Gross profit stayed firm with margins at 90% in Q4 2023 versus 72% in Q1 2023. Operating income totaled $2.16M in Q4 2023, maintaining a 3177% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $2.30M. Net income rose to $1.88M, with EPS at $2.20. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan